Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger, Inc. (Nasdaq: SDGR) announced new preclinical data on its small-molecule MALT1 inhibitors, to be presented at the American Society of Hematology's Annual Meeting from December 11-14, 2021, in Atlanta, Georgia. MALT1 inhibitors are a promising therapeutic route for certain non-Hodgkin B-cell lymphomas and chronic lymphocytic leukemia (CLL). The lead MALT1 inhibitor is expected to enter clinical trials next year. The presentation will cover characterization details, which may enhance investor interest and highlight the company's innovative drug discovery approach.

Schrödinger (Nasdaq: SDGR) will host a conference call on November 10, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial results. The call will provide an update on the company's business and can be accessed via its website's investor section. Schrödinger specializes in a physics-based software platform aimed at revolutionizing therapeutic and material discovery, offering faster and cost-effective solutions for its clients in multiple sectors.

Schrödinger (Nasdaq:SDGR) and Centessa Pharmaceuticals (Nasdaq:CNTA) announced an exclusive collaboration to discover novel therapeutics targeting the orexin-2 receptor (OX2R), relevant for sleep disorders like narcolepsy. This partnership marks the first large-scale application of Schrödinger's computational platform in orexin agonist development, leveraging Orexia’s structural biology capabilities. Orexia will manage preclinical research and commercialization, while Schrödinger will receive upfront payments and potential royalties on global sales. The collaboration aims to explore orexin agonists for various disorders characterized by excessive daytime sleepiness.

Schrödinger, Inc. (Nasdaq: SDGR) announced on October 15, 2021 that it granted stock options for 35,550 shares to 13 new employees, as part of its 2021 Inducement Equity Incentive Plan. The options have an exercise price of $55.36 per share, matching the company's closing stock price on the granting date. These options will vest over four years, with 25% vesting after one year, and the remainder in monthly installments over the following three years. This move aims to attract talent and incentivize long-term commitment from the new hires.

Schrödinger, Inc. (Nasdaq: SDGR) has announced a strategic two-year collaboration with The University of Texas MD Anderson Cancer Center to advance its WEE1 inhibitor program. The partnership aims to optimize therapeutic development through biomarker-driven patient stratification and clinical study prioritization. Schrödinger's WEE1 inhibitors showed promising preclinical results, and the collaboration will investigate their potential as single agents and in combination therapies for specific cancer types. Schrödinger retains sole responsibility for development and commercialization of these compounds.

Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options for 45,050 shares to 15 newly hired employees on September 17, 2021. This initiative, part of the 2021 Inducement Equity Incentive Plan, aims to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $62.42, equal to the stock's closing price on the grant date. The options vest over four years, incentivizing employee retention and long-term commitment.

Schrödinger (Nasdaq: SDGR) has announced its participation in four investor conferences in September 2021. On September 9 at 2:00 p.m. ET, the company will present at the Morgan Stanley 19th Annual Global Healthcare Conference. A pre-recorded presentation will be available on September 13. Additionally, Schrödinger will participate in the BofA Global Healthcare Conference on September 16 and the BofA Securities Drug Discovery Conference on September 20. Live webcasts can be accessed on their website and will be archived for about seven days.

Schrödinger, Inc. (Nasdaq: SDGR) recently granted stock options to 13 new employees, totaling 25,150 shares under its 2021 Inducement Equity Incentive Plan. The options, priced at $57.40 per share, were approved by the compensation committee and are intended to attract talent. Each option has a 10-year term, vesting over four years. Schrödinger's innovative software platform advances drug development and material science, serving clients globally to accelerate the discovery of novel therapeutics.

Schrödinger (Nasdaq: SDGR) announced a 29% increase in Q2 2021 revenue to $29.8 million, with software revenue rising 15% to $24.1 million. The company reported a gross profit of $12 million, though overall operating expenses grew to $42.3 million, leading to a net loss of $34.6 million. Notably, Schrödinger has partnered with Zai Lab to co-develop an oncology program, and expects to submit up to three IND applications in 2022. The company anticipates full-year revenue between $124 million and $142 million. Cash and equivalents totaled $616.6 million as of June 30, 2021.